Uremic muscle atrophy is a complex and progressive disease. The elderly in particular are prone to renal failure, which can accelerate physiological muscle wasting in older age groups. This serious complication not only contributes to original lifestyle changes and reduced quality of life, but can also increase cardiovascular complications, morbidity and mortality. Despite this serious threat of muscle atrophy, treatment of muscle density reduction in patients with CKD suggests that clinicians are beginning to take the complications of end-stage renal disease patients seriously, despite being pathologically advanced or irreversible. Considering the muscle atrophy of CKD patients and the general health care system, patients with mild-to-moderate kidney injury should be reasonably studied when muscle complications are still reversible, applying therapeutic strategies to maintain and repair skeletal muscle homeostasis.